| Quarter (USD) | Sep 24 | Jun 24 | Mar 24 | Dec 23 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 116.50 mm | 116.50 mm | 116.50 mm | 116.50 mm | 116.50 mm | 116.50 mm |
| Cash burn (monthly) | (no burn) | (no burn) | 24.04 mm | 16.68 mm | 16.73 mm | 10.39 mm |
| Cash used (since last report) | n/a | n/a | 105.50 mm | 73.21 mm | 73.42 mm | 45.59 mm |
| Cash remaining | n/a | n/a | 11.00 mm | 43.29 mm | 43.08 mm | 70.91 mm |
| Runway (months of cash) | n/a | n/a | 0.5 | 2.6 | 2.6 | 6.8 |
| 13F holders | Current |
|---|---|
| Total holders | 177 |
| Opened positions | 38 |
| Closed positions | 19 |
| Increased positions | 55 |
| Reduced positions | 64 |
| 13F shares | Current |
|---|---|
| Total value | 2.93 tn |
| Total shares | 78.97 mm |
| Total puts | 81.70 k |
| Total calls | 50.60 k |
| Total put/call ratio | 1.6 |
| Largest owners | Shares | Value |
|---|---|---|
| T. Rowe Price | 6.65 mm | $314.53 mm |
| Baker Bros. Advisors | 6.00 mm | $283.79 bn |
| Biotechnology Value Fund L P | 5.83 mm | $158.49 mm |
| BVF | 5.16 mm | $244.31 bn |
| FMR | 5.11 mm | $241.82 bn |
| Atlas Venture Life Science Advisors | 4.90 mm | $231.75 bn |
| Vanguard | 4.75 mm | $225.00 bn |
| Wellington Management | 4.62 mm | $218.59 bn |
| Avoro Capital Advisors | 4.50 mm | $212.99 bn |
| BlackRock | 4.21 mm | $199.34 bn |
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 10 Jan 25 | Nello Mainolfi | Common Stock | Option exercise | Acquire M | No | No | 2.08 | 10,000 | 20.80 k | 659,959 |
| 10 Jan 25 | Nello Mainolfi | Stock Option Common Stock | Option exercise | Acquire M | No | No | 2.08 | 10,000 | 20.80 k | 495,559 |
| 10 Jan 25 | Bruce N. Jacobs | Common Stock | Option exercise | Acquire M | No | No | 2.08 | 10,000 | 20.80 k | 178,921 |
| 10 Jan 25 | Bruce N. Jacobs | Stock Option Common Stock | Option exercise | Dispose M | No | No | 2.08 | 10,000 | 20.80 k | 94,899 |
| 6 Jan 25 | Ellen Chiniara | Common Stock | Sell | Dispose S | No | No | 41.7529 | 3,129 | 130.64 k | 54,826 |
| 2 Dec 24 | Esposito Pamela | Common Stock | Sell | Dispose S | No | Yes | 49 | 2,500 | 122.50 k | 0 |
| 2 Dec 24 | Esposito Pamela | Common Stock | Option exercise | Acquire M | No | Yes | 29.55 | 2,500 | 73.88 k | 2,500 |
| 2 Dec 24 | Esposito Pamela | Stock Option Common Stock | Option exercise | Dispose M | No | Yes | 29.55 | 2,500 | 73.88 k | 29,127 |
| 17 Sep 24 | Esposito Pamela | Common Stock | Sell | Dispose S | No | Yes | 48.7526 | 7,150 | 348.58 k | 0 |
| 17 Sep 24 | Esposito Pamela | Common Stock | Sell | Dispose S | No | Yes | 47.7456 | 6,350 | 303.18 k | 7,150 |
